Merozoite surface protein 1 lacking glycosylation sites

Details Merozoite surface protein 1 lacking glycosylation sites Merozoite surface protein 1 lacking glycosylation sites

2008-04-08

2008-04-08

Crouch, Deborah (Department: 1632)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Parasitic organism or component thereof or substance...

C424S191100, C800S007000, C800S014000, C800S015000, C800S016000, C800S017000, C800S018000, C530S395000, C514S012200

Reexamination Certificate

active

07354594

ABSTRACT:
The invention provides modified recombinant nucleic acid sequences (preferably DNA) and methods for increasing the mRNA levels and protein expression of malarial surface protein MSP-1 which is known to be difficult to express in cell culture systems, mammalian cell culture systems, or in transgenic animals. The preferred protein candidates for expression using the recombinant techniques of the invention are MSP-1 proteins expressed from DNA coding sequences comprising reduced overall AT content or AT rich regions and/or mRNA instability motifs and/or rare codons relative to the native MSP-1 gene.

REFERENCES:
patent: 4873316 (1989-10-01), Meade et al.
patent: 5194587 (1993-03-01), Knapp et al.
patent: 5225534 (1993-07-01), Certa
patent: 5231168 (1993-07-01), Dziegiel et al.
patent: 5304489 (1994-04-01), Rosen
patent: 5395614 (1995-03-01), Knapp et al.
patent: 5530177 (1996-06-01), Bleck et al.
patent: 5543323 (1996-08-01), Ridley et al.
patent: 5643578 (1997-07-01), Robinson et al.
patent: 5646247 (1997-07-01), Barnwell et al.
patent: 5736131 (1998-04-01), Bosch et al.
patent: 5795737 (1998-08-01), Seed et al.
patent: 5856178 (1999-01-01), White et al.
patent: 6114148 (2000-09-01), Seed et al.
patent: 6130062 (2000-10-01), Milland et al.
patent: 6593463 (2003-07-01), Chen et al.
patent: 2002/0144299 (2002-10-01), Chen et al.
patent: 2005/0071890 (2005-03-01), Chen et al.
patent: 2005/0235371 (2005-10-01), Chen et al.
patent: 1997 48649 (1998-04-01), None
patent: 727864 (2001-01-01), None
patent: 0264166 (1988-04-01), None
patent: 0359472 (1990-03-01), None
patent: 0682115 (1995-11-01), None
patent: 0923308 (1997-11-01), None
patent: WO-91/08216 (1991-06-01), None
patent: WO 91/18922 (1991-12-01), None
patent: WO 94/05796 (1994-03-01), None
patent: WO-94/28930 (1994-12-01), None
patent: WO 95/17085 (1995-06-01), None
patent: WO 96/03051 (1996-02-01), None
patent: WO 97/26911 (1997-07-01), None
patent: WO 97/30158 (1997-08-01), None
patent: WO 97/30159 (1997-08-01), None
patent: WO-97/31115 (1997-08-01), None
patent: WO-98/14583 (1998-04-01), None
patent: WO-99/20766 (1999-04-01), None
patent: WO-99/20774 (1999-04-01), None
Holder et al. Primary Structure of the Precursor to the Three Major Surface Antigens ofPlamodium falciparumMeroziotes. Nature. Sep. 19, 1985, vol. 317, pp. 270-273.
Holder et al. Processing of the Precursor to the Major Meroziote Surface Antigens ofPlasmodium falciparum. Parasitology. 1987, vol. 94, pp. 199-208.
Siddiqui et al. Merozoite Surface Coat Precursor Protein Completely Protects Aotus Monkeys AgainstPlasmodium falciparumMalaria. Proced. Natal. Acad. Sci.. May 1987, vol. 84, pp. 3014-3018.
[No Author Listed] Product pd(N)6 in the Pharmacia Biotech Catalogue. 1995. p. 277.
GenBank Submission; NIH/NCBI, Accession No. L48364. Lukashov et al. Feb. 28, 1996.
Akashi et al., Number and location of AUUUA motifs: role in regulating transiently expressed RNAs. Blood. Jun. 1, 1994;83(11):3182-7.
Brinster et al., Factors affecting the efficiency of introducing foreign DNA into mice by microinjecting eggs. Proc Natl Acad Sci U S A. Jul. 1985;82(13):4438-42.
Buhler et al., Rabbit beta-casein promoter directs secretion of human interleukin-2 into the milk of transgenic rabbits. Biotechnology (N Y). Feb. 1990;8(2):140-3.
Campbell et al., Sheep cloned by nuclear transfer from a cultured cell line. Nature. Mar. 7, 1996;380(6569):64-6.
Chang et al., Generalized immunological recognition of the major merozoite surface antigen (gp195) ofPlasmodium falciparum. Proc Natl Acad Sci U S A. Aug. 1989;86(16):6343-7.
Chang et al., A carboxyl-terminal fragment ofPlasmodium falciparumgp195 expressed by a recombinant baculovirus induces antibodies that completely inhibit parasite growth. J Immunol. Jul. 15, 1992;149(2):548-55.
Chang et al., A recombinant baculovirus 42-kilodalton C-terminal fragment ofPlasmodium falciparummerozoite surface protein 1 protects Aotus monkeys against malaria. Infect Immun. Jan. 1996;64(1):253-61.
Chattergoon et al., Genetic immunization: a new era in vaccines and immune therapeutics. FASEB J. Aug. 1997;11(10):753-63.
Dame et al., Current status of thePlasmodium falciparumgenome project. Mol Biochem Parasitol. Jul. 1996;79(1):1-12.
Diggs et al., The major merozoite surface protein as a malaria vaccine target. Parasitol Today. Aug. 1993;9(8):300-2.
D'Orso et al., TcUBP-1, a developmentally regulated U-rich RNA-binding protein involved in selective mRNA destabilization in trypanosomes. J Biol Chem. Sep. 14, 2001;276(37):34801-9. Epub Jul. 2, 2001.
Ebert et al., Transgenic production of a varient of human tissue-type plasminogen activator in goat milk: generation of transgenic goats and analysis of expression. Biotechnology (N Y). Sep. 1991;9(9):835-8.
Gardner et al., DNA vaccines against malaria: immunogenicity and protection in a rodent model. J Pharm Sci. Dec. 1996;85(12):1294-300.
Gordon et al., Genetic transformation of mouse embryos by microinjection of purified DNA. Proc Natl Acad Sci U S A. Dec. 1980;77(12):7380-4.
Gordon et al., Integration and stable germ line transmission of genes injected into mouse pronuclei. Science. Dec. 11, 1981;214(4526):1244-6.
Graves et al., Comparison of the cost-effectiveness of vaccines and insecticide impregnation of mosquito nets for the prevention of malaria. Ann Trop Med Parasitol. Jun. 1998;92(4):399-410.
Graves et al., Vaccines for preventing malaria. Cochrane Database Syst Rev. 2003;(1):CD000129.
Gutierrez et al., Expression of a bovine kappa-CN cDNA in the mammary gland of transgenic mice utilizing a genomic milk protein gene as an expression cassette. Transgenic Res. Jul. 1996;5(4):271-9.
Hochi et al., Secretion of bovine alpha-lactalbumin into the milk of transgenic rats. Mol Reprod Dev. Oct. 1992;33(2):160-4.
Holder et al., Primary structure of the precursor to the three major surface antigens ofPlasmodium falciparummerozoites. Nature. Sep. 19-25, 1985;317(6034):270-3.
Jenkins et al., Evolution of base composition and codon usage bias in the genus Flavivirus. J Mol Evol. Apr. 2001;52(4):383-90.
Jongwutiwes et al., Sequence conservation in the C-terminal part of the precursor to the major merozoite surface proteins (MSP1) ofPlasmodium falciparumfrom field isolates. Mol Biochem Parasitol. May 1993;59(1):95-100.
Kalinna et al., DNA vaccines for parasitic infections. Immunol Cell Biol. Aug. 1997;75(4):370-5.
Krimpenfort et al., Generation of transgenic dairy cattle using ‘in vitro’ embryo production. Biotechnology (N Y). Sep. 1991;9(9):844-7.
Ledley et al., Clinical considerations in the design of protocols for somatic gene therapy. Hum Gene Ther. 1991 Spring;2(1):77-83.
Liebhaber et al., mRNA stability and the control of gene expression. Nucleic Acids Symp Ser. 1997;(36):29-32.
Martin et al., Total synthesis and expression inEscherichia coliof a gene encoding human tropoelastin. Gene. Mar. 10, 1995; 154(2):159-66.
McDonnell et al., DNA vaccines. N Engl J Med. Jan. 4, 1996;334(1):42-5.
Nuijens et al., Characterization of recombinant human lactoferrin secreted in milk of transgenic mice. J Biol Chem. Mar. 28, 1997;272(13):8802-7.
Orkin et al., Report and recommendations of panel to access NIH investment in Gene Therapy Res. 1995.
Palmiter et al., Transgenic mice. Cell. Jun. 1985;41(2):343-5.
Perlak et al., Modification of the coding sequence enhances plant expression of insect control protein genes. Proc Natl Acad Sci U S A. Apr. 15, 1991;88(8):3324-8.
Prapunwattana et al., Chemical synthesis of thePlasmodium falciparumdihydrofolate reductase-thymidylate synthase gene. Mol Biochem Parasitol. Dec. 2, 1996;83(1):93-106.
Senior et al., DNA vaccine shows promise for malaria. Mol Med Today. Jan. 1999; 5(1):2-3.
Shani et al., Expression of human serum albumin in the milk of transgenic mice. Transgenic Res. Sep. 1992;1(5):195-208.
Shaw et al., A conserved AU sequence from the 3' untranslated region of GM-CSF mRNA mediates selective mRNA degradation. Cell. Aug. 29, 1986;46(5):659-67.
Simons et al., Gene transfer into sheep. Bio/Technology. 1988;6:179-83.
Soulier et al., Expression analysis of ruminant alpha

Affiliated with

Also associated with

Rating

Merozoite surface protein 1 lacking glycosylation sites does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Merozoite surface protein 1 lacking glycosylation sites, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Merozoite surface protein 1 lacking glycosylation sites will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2748062